Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (<scp>SYNCHRONIZE™</scp>‐1 and ‐2)
These trials are designed to provide robust evaluation of the efficacy, safety, and tolerability of survodutide for the treatment of obesity in the presence or absence of T2D.
Authors
- Anna Unseld
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Ania M. Jastreboff (ORCID: https://orcid.org/0000-0003-1446-0991)
- Martina Brueckmann (ORCID: https://orcid.org/0000-0003-1215-0746)
- Sean Wharton (ORCID: https://orcid.org/0000-0003-0111-1530)
- Sue D. Pedersen (ORCID: https://orcid.org/0000-0002-4355-1764)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Elke Platz
- Lee M. Kaplan (ORCID: https://orcid.org/0000-0002-6301-2696)
- Isabel M. Kloer
- Samina Ajaz Hussain (ORCID: https://orcid.org/0009-0002-4849-0363)
- Luiza Borowska
Institutions
- University College Dublin (IE)
- Dartmouth College (US)
- Brigham and Women's Hospital (US)
- Boehringer Ingelheim (Germany) (DE)
- Harvard University (US)
- University of Calgary (CA)
- University of Mannheim (DE)
- University of Toronto (CA)
- Heidelberg University (DE)
- LMC Diabetes & Endocrinology (Canada) (CA)
- St. Vincent's University Hospital (IE)
- Troy Gastroenterology (US)
- Saint Luke's Hospital (US)
- University of Missouri–Kansas City (US)
- McMaster University (CA)
Publication Details
- Journal
- Obesity
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1002/oby.24184
- Citations
- 21
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 7.51